GlassScriptPhysician profile
Delores Macksoud
NPI 1962594580
$13,825.17
in general payments reported to CMS, 2019-2025
51 companies · $396 in 2025
The $396 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,098 · 2020: $1,455 · 2021: $2,034 · 2022: $4,701 · 2023: $2,374 · 2024: $767 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,501 · Education: $36.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.00 |
| Education | $36.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,246.04 | 2020-2025 | |
| Emd Serono, INC. | $1,945.69 | 2020-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,178.11 | 2019-2023 | Vumerity, Plegridy, Avonex |
| Ucb, INC. | $1,133.77 | 2019-2024 | Rystiggo, Briviact |
| Amneal Pharmaceuticals LLC | $815.02 | 2019-2024 | Rytary |
| Genzyme Corporation | $767.98 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $680.23 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Adamas Pharmaceuticals, INC. | $412.54 | 2019-2021 | |
| Lilly USA, LLC | $330.71 | 2019-2023 | Emgality, Amyvid |
| Allergan, INC. | $295.46 | 2019-2022 | |
| Argenx US, INC. | $270.59 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $243.95 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $232.70 | 2019-2024 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $191.46 | 2019-2023 | Ultomiris |
| Viiv Healthcare Company | $164.11 | 2024-2025 | Rukobia, Apretude, Dovato |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delores Macksoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.